The A-share innovative drug sector saw a volatile rise, with Shutaishan hitting the 20% daily limit. Tianjin Pharmaceutical had previously hit the daily limit, while Baili Tianheng, Betta Pharmaceuticals, Jinbo Biotechnology, Nanjing Xinjie, and Tongrentang followed suit.